These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 14603611)

  • 1. [Beta-1 blockade plus NO release. Additional organ protection for patients with hypertension].
    MMW Fortschr Med; 2003 Oct; 145(40):57. PubMed ID: 14603611
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beta blocker improves the endothelial function. Gas-forming blood vessel protection].
    MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974334
    [No Abstract]   [Full Text] [Related]  

  • 3. [Beta blockade plus NO release. Patients with heart failure can be loaded more].
    MMW Fortschr Med; 2002 Oct; 144(41):57. PubMed ID: 12474368
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Beta blocker activates release of NO. Radical against atherosclerosis].
    MMW Fortschr Med; 2004 Mar; 146(11):57. PubMed ID: 15152777
    [No Abstract]   [Full Text] [Related]  

  • 6. Nebivolol: a new beta blocker on the horizon.
    Katira R; Chauhan A
    Indian Heart J; 2000; 52(1):86-8. PubMed ID: 10820942
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL; Basile JN; Giles TD; Taylor AA
    Am J Med; 2010 Jul; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents.
    Sarafidis PA; Bakris GL
    J Hypertens; 2007 Jan; 25(1):249-52; author reply 252-3. PubMed ID: 17143201
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
    Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
    Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Initial data on nebivolol in heart failure. Beta blockers strengthen older hearts, too].
    MMW Fortschr Med; 2003 May; 145(22):55. PubMed ID: 12866284
    [No Abstract]   [Full Text] [Related]  

  • 14. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure.
    Ambrosio G; Flather MD; Böhm M; Cohen-Solal A; Murrone A; Mascagni F; Spinucci G; Conti MG; van Veldhuisen DJ; Tavazzi L; Coats AJ
    Heart; 2011 Feb; 97(3):209-14. PubMed ID: 21138861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nebivolol: a beta blocker with vasodilator properties].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(15):631-3. PubMed ID: 10804847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vasodilating beta blockers as effective antihypertensive agents. Results of a multicenter observational study].
    von Fallois J; Faulhaber HD
    MMW Fortschr Med; 2000 Jun; 142(24):45. PubMed ID: 10895582
    [No Abstract]   [Full Text] [Related]  

  • 20. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.